What's New
Glucagon-like peptide-1 receptor agonists (dulaglutide, liraglutide, semaglutide, tirzepatide) and acute persistent visual loss
Medsafe has published a new monitoring communication highlighting the potential risk of acute persistent visual loss in individuals using glucagon-like peptide-1 receptor agonists, also referred to as GLP-1 receptor agonists.
We encourage healthcare professionals and consumers to report any suspected acute persistent visual loss associated with use of GLP-1 receptor agonists. Anyone can submit a report.
News and Events
| Date | Type | Title |
|---|---|---|
| 26/1/2026 | Monitoring Communication |  Glucagon-like peptide-1 receptor agonists (dulaglutide, liraglutide, semaglutide, tirzepatide) and acute persistent visual loss monitoring closes 26 July 2026 |
| 15/1/2026 | Notices | Updated Clinical Trial Guidelines |
| 15/1/2026 | Consultation | Outcome of the consultation on the proposed updates to the Guideline on the Regulation of Therapeutic Products in New Zealand: Clinical Trials |
| 15/1/2026 | Consultation | Proposed extension of the abbreviated procedure for new medicine applications and section 24(5)(a) notifications |
| 7/1/2026 | Notices | Notice of Medsafe Office Closure Christmas/New Year 2025/2026 |
| 23/12/2025 | Committees | Medicines Classification Committee - Dates and Deadlines |
| 23/12/2025 | Committees | Minutes of the 75th meeting of the Medicines Classification Committee - 19 November 2025 |
| 23/12/2025 | Committees | Medicines Classification Committee Vacancies |
